Linearis has inaugurated a new laboratory in the greater Quebec City region and introduced its high-throughput metabolomics platform, which integrates artificial intelligence (AI) to support life sciences projects to accelerate the benefits to patients.

The integration of AI and automated high-throughput analyses of approximately 1,300 metabolic biomarkers enables Linearis to provide tailored services to biobanks, clinical research groups, and biopharmaceutical companies in identifying various elements linked to metabolic diseases such as cancer, diabetes, and antimicrobial resistance, aiming to enhance prevention, screening, treatment monitoring, and the discovery of new drugs.

“The launch of our high-throughput metabolomics laboratory, combined with our investment fund, marks a pivotal step in establishing a true biohub at the intersection of AI-life sciences. This integrated model enables us to support the ecosystem better while accelerating the transformation of scientific discoveries into real-world solutions for patients,” stated Alexandre Le Bouthillier, PhD, CEO of Linearis.